文献速递神经肿瘤

复发高级别胶质瘤低分次立体定向再照射联合帕博利珠单抗与贝伐珠单抗的I期研究

Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study.
PubMed 文献 · Neuro Oncol · 2021-01-01

结果显示该联合方案总体安全可耐受,贝伐珠单抗初治患者中83%达到完全或部分缓解,贝伐珠单抗耐药患者中62%达到部分缓解。

要点

  • 联合方案在复发高级别胶质瘤中总体安全可耐受。
  • 贝伐珠单抗初治者20例(83%)达完全或部分缓解。
  • 贝伐珠单抗耐药者5例(62%)达部分缓解。

核心结论

  • HFSRT联合帕博利珠单抗与贝伐珠单抗治疗复发高级别胶质瘤总体安全且耐受良好,值得进一步研究HFSRT联合免疫治疗。

研究设计与样本

  • 帕博利珠单抗100或200 mg按剂量水平每3周一次,同期HFSRT 30 Gy分5次,贝伐珠单抗10 mg/kg每2周一次。

主要发现

  • 最常见治疗相关不良事件为蛋白尿(40.6%)、乏力(25%)、丙氨酸氨基转移酶升高(25%)和高血压(25%)。
  • 1例因3级天冬氨酸氨基转移酶升高导致治疗中断。
  • 贝伐珠单抗初治队列中位总生存13.45个月(95%CI:9.46-18.46),中位无进展生存7.92个月(95%CI:6.31-12.45)。
  • 贝伐珠单抗耐药队列中位总生存9.3个月(95%CI:8.97-18.86),中位无进展生存6.54个月(95%CI:5.95-18.86)。
  • 多数患者(20/26,77%)肿瘤细胞/肿瘤微环境PD-L1表达<1%。

临床怎么用

  • 该联合方案可作为复发高级别胶质瘤的潜在治疗选择,但需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy may synergize with programmed cell death 1 (PD1)/PD1 ligand (PD-L1) blockade. The purpose of this study was to determine the recommended phase II dose, safety/tolerability, and preliminary efficacy of combining pembrolizumab, an anti-PD1 monoclonal antibody, with hypofractionated stereotactic irradiation (HFSRT) and bevacizumab in patients with recurrent high-grade gliomas (HGGs). METHODS: Eligible subjects with recurrent glioblastoma or anaplastic astrocytoma were treated with pembrolizumab (100 or 200 mg based on dose level Q3W) concurrently with HFSRT (30 Gy in 5 fractions) and bevacizumab 10 mg/kg Q2W. RESULTS: Thirty-two patients were enrolled (bevacizumab-naïve, n = 24; bevacizumab-resistant, n = 8). The most common treatment-related adverse events (TRAEs) were proteinuria (40.6%), fatigue (25%), increased alanine aminotransferase (25%), and hypertension (25%). TRAEs leading to discontinuation occurred in 1 patient who experienced a grade 3 elevation of aspartate aminotransferase. In the bevacizumab-naïve cohort, 20 patients (83%) had a complete response or partial response. The median overall survival (OS) and progression-free survival (PFS) were 13.45 months (95% CI: 9.46-18.46) and 7.92 months (95% CI: 6.31-12.45), respectively. In the bevacizumab-resistant cohort, PR was achieved in 5 patients (62%). Median OS was 9.3 months (95% CI: 8.97-18.86) with a median PFS of 6.54 months (95% CI: 5.95-18.86). The majority of patients (n = 20/26; 77%) had tumor-cell/tumor-microenvironment PD-L1 expression <1%. CONCLUSIONS: The combination of HFSRT with pembrolizumab and bevacizumab in patients with recurrent HGG is generally safe and well tolerated. These findings merit further investigation of HFSRT with immunotherapy in HGGs.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Sahebjam S, Forsyth PA, Tran ND, et al. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neuro Oncol. 2021. PMID: 33173935. doi:10.1093/neuonc/noaa260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。